Parliamentary questions

Every parliamentary question asked in the 34th Dáil within the archive window, browsable by the department it was addressed to. Department names appear as printed in the official record. Questions also carry the questions paper's own subject heading. Browse those on the Topics page.

Questions by department

Addressed toQuestionsOralWrittenShare
Health 25,558 130 25,428
Education 12,997 131 12,866
Transport 9,871 127 9,744
Justice 9,003 122 8,881
Housing 8,661 147 8,514
Children 8,209 116 8,093
Social 5,425 121 5,304
Finance 5,250 139 5,111
Agriculture 4,588 123 4,465
Foreign 3,683 177 3,506
Enterprise 3,667 126 3,541
Climate 3,477 98 3,379
Public Expenditure 3,404 151 3,253
Further and Higher Education 3,269 127 3,142
Taoiseach 2,460 1,354 1,106
Defence 2,410 162 2,248
Culture 2,221 131 2,090
Rural 2,199 121 2,078
Environment 1,029 26 1,003
Tourism 703 31 672

Browse questions

Clear

25,558 questions match these filters · page 137 of 1,023

Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1134. Deputy Ken O'Flynn asked the Minister for Health the division of the HSE or Department of Health that holds responsibility for estimating the number of patients clinically eligible for orphan medicinal products approved for reimbursement in the State (details supplied). [38846/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1135. Deputy Ken O'Flynn asked the Minister for Health if any budget impact assessment, cost projection, prevalence estimate, or epidemiological model was prepared in advance of reimbursement consideration for omaveloxolone (skyclarys); and the details of same. [38847/26]
Ken O'Flynn written 2026-05-26 · to Health · Disease Management
1136. Deputy Ken O'Flynn asked the Minister for Health if the HSE maintains a national registry, prevalence estimate or centrally collated dataset for Friedreich's ataxia patients in the State. [38848/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1137. Deputy Ken O'Flynn asked the Minister for Health how reimbursement decisions for high-cost orphan medicines are financially planned where the HSE does not centrally retain data regarding the number of clinically eligible patients. [38849/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1138. Deputy Ken O'Flynn asked the Minister for Health if the National Centre for Pharmacoeconomics, the HSE medicines management programme, or any external body estimated the likely eligible patient cohort for omaveloxolone (skyclarys) prior to reimbursement consideration. [38850/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1139. Deputy Ken O'Flynn asked the Minister for Health if any hospitals, hospital groups, or specialist neurology centres currently facilitate access to omaveloxolone (skyclarys) through named-patient arrangements, manufacturer-supported supply, or exceptional approval mechanisms outside PCRS reimbursement pathways. [38854/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1140. Deputy Ken O'Flynn asked the Minister for Health if the HSE maintains any national policy governing interim patient access to medicines awaiting reimbursement decisions for rare diseases. [38855/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1141. Deputy Ken O'Flynn asked the Minister for Health if the Department or HSE has examined establishing a formal compassionate or early-access medicines framework for patients with rare progressive conditions pending health technology assistant and reimbursement determinations. [38856/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1142. Deputy Ken O'Flynn asked the Minister for Health the number of reimbursement applications for orphan or ultra-orphan medicines remain under assessment by the HSE for more than 12 months as of May 2026. [38857/26]
Ken O'Flynn written 2026-05-26 · to Health · Medicinal Products
1143. Deputy Ken O'Flynn asked the Minister for Health if the HSE records the number of patients who seek access to medicines through named-patient or exceptional approval mechanisms outside standard reimbursement arrangements. [38858/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1144. Deputy Ken O'Flynn asked the Minister for Health whether any patient safety review, adverse incident review, or clinical governance review has examined the impact of prolonged ambulance dispatch or allocation delays on patient outcomes since 2020; and if so, to provide details. [38862/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1145. Deputy Ken O'Flynn asked the Minister for Health whether the National Ambulance Service operates under any internally defined escalation thresholds for excessive dispatch delay, delayed resource allocation, or prolonged queue times for emergency incidents; and if so, to provide details. [38863/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1146. Deputy Ken O'Flynn asked the Minister for Health whether any review has been conducted regarding whether Ireland's current ambulance dispatch governance framework aligns with international best practice standards in comparable jurisdictions; and if so, to provide details. [38864/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1147. Deputy Ken O'Flynn asked the Minister for Health whether any statutory instrument, policy directive, governance framework, operational standard, or national clinical guideline formally defines acceptable maximum ambulance dispatch times in Ireland. [38865/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1148. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE maintains any national dataset recording ambulance incidents where dispatch allocation exceeded a specified time threshold; and if not, whether consideration has been given to establishing such reporting mechanisms. [38866/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1149. Deputy Ken O'Flynn asked the Minister for Health whether the National Ambulance Service defines any ambulance response delay duration as constituting a potential patient safety incident in and of itself; and if so, the thresholds applied. [38877/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1150. Deputy Ken O'Flynn asked the Minister for Health whether any ambulance delays exceeding 60 minutes resulted in incident reviews, serious incident assessments, or patient-safety escalations in 2024, 2025 or to date in 2026. [38878/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1151. Deputy Ken O'Flynn asked the Minister for Health whether the HSE Incident Management Framework contains any specific provisions relating to prolonged ambulance response delays. [38879/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1152. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health has assessed whether the absence of national reporting on extreme ambulance delays limits oversight of patient safety risks. [38880/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1153. Deputy Ken O'Flynn asked the Minister for Health whether HIQA has ever been requested to examine governance arrangements relating to prolonged ambulance response times. [38881/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1154. Deputy Ken O'Flynn asked the Minister for Health whether ambulance delays are incorporated into any corporate, enterprise, or clinical risk registers maintained by the HSE or National Ambulance Service. [38882/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1155. Deputy Ken O'Flynn asked the Minister for Health whether the Department receives any routine exception reporting where NAS response performance materially deteriorates below National Service Plan KPI levels. [38883/26]
Ken O'Flynn written 2026-05-26 · to Health · Ambulance Service
1156. Deputy Ken O'Flynn asked the Minister for Health whether any internal review has examined whether prolonged ambulance delays should constitute automatically reportable adverse incidents. [38884/26]
Ken O'Flynn written 2026-05-26 · to Health · Health Services
1157. Deputy Ken O'Flynn asked the Minister for Health if her Department maintains a central register identifying all statutory, non-statutory, intermediary-funded, and externally governed bodies receiving funding from the Department or the HSE; and if not, whether such a register will be established. [38919/26]
Ken O'Flynn written 2026-05-26 · to Health · Health Services
1158. Deputy Ken O'Flynn asked the Minister for Health whether any formal criteria or classification methodology is used by the Department or the HSE to determine whether a publicly funded organisation is categorised as statutory, non-statutory, voluntary, intermediary-funded, or publicly controlled for governance purposes; and if so, to provide details. [38920/26]
← Previous Next → page 137 of 1,023